Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial

investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-superior-oral-semaglutide-head

Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial
For the primary endpoint, orforglipron lowered A1C by 2.2% vs. 1.4% with oral semaglutide at the highest doses
Participants taking the highest dose of orforglipron lost an average of 19.7 lbs (9.2%) vs.…

This story appeared on investor.lilly.com, 2025-09-17 15:56:52.630000.
The Entire Business World on a Single Page. Free to Use →